Table 1 (abstract P310). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | Our study (10 years) | Hari P et al (10 years) | Srivastava et al (25 years) | S.Singh et al (24 years) | Samanta et al (12 years) |
|---|---|---|---|---|---|
Sample size | 60 | 54 | 134 | 72 | 46 |
Male: female | 1:4.45 | 1:2.9 | 1:9.3 | 1:3.23 | 1:1.7 |
Number of biopsy proven cases | 60 | 54 | 92 | 53 | 41 |
Mean age of diagnosis of LN (years) | 11.9± 3.38 | 10.4±2.6 | 13.5±3.7 | 10.5±2.1 | 10.2±2.43 |
Duration between diagnosis of SLE and LN | 3.53± 10 months | NR | 1.87±2.5 years | 9.4±12.6 months | 8.5±10 months |
Lupus nephritis at presentation | 60% | NR | 82.8% | 76.45% | 82.6% |
Clinical features | n=60 | n=54 | n=92 | n=72 | n=46 |
 Fever | 88.3% | 62.9% | 98.9% | 87.5% | NR |
 Arthritis | 58.33% | 42.6% | 78.2% | 52.8% | NR |
 Hypertension | 40% | 55.6% | 32.1% | NR | NR |
 Headache | 33.33% | NR | 7.6% | NR | NR |
 CNS involvement | 18.33% | 14.8% | 31.5% | 23.6% | 28.2% |
 Photosensitivity | 51.67% | 22.2% | NR | 38.9% | NR |
 Oral/palatal ulcer | 40% | 29.6% | 31.5% | NR | NR |
Laboratory features | |||||
 ANA (+) | 100% | 96.3% | 97.7% | 94.4% | 97.8% |
 Anti-dsDNA(+) | 91.11% | 57.4% | 85.4% | 87.5% | 82.6% |
 Low C3 | 60.34% | NR | 75.8% | 81.8% | 76.09% |
Renal biopsy | |||||
 Class II | 16.67% | 18.51% | 14.2% | 18.9% | 26.09% |
 Class III | 25% | 11.1% | 26% | 1.9% | 23.91% |
 Class IV | 41.66% | 48.1% | 46.7% | 66.0% | 30.43% |
 Class V | 3.33% | 12.9% | 13.1% | 13.2% | 8.7% |
 Class III+V | 8.33% | NR | NR | NR | NR |
 Class IV+V | 1.67% | NR | NR | NR | NR |
 Class II+III | 1.67% | NR | NR | NR | NR |